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began therapy on a conventional medication, while 1,035
(24%) started on an atypical medication. Only 67 pa-
tients initiated treatment using 2 antipsychotics simul-
taneously. Time-to-event analysis of treatment discontin-
uation (mono-atypical vs. mono-conventional vs. multi-
therapy) found that the probabilities of discontinuing
therapy differed by year of prescription. In more current
prescription years, patients initiating atypical therapy
were more likely to remain on therapy than those starting
on conventional agents. CONCLUSION: Atypical agents
appear to provide improved performance in treatment
continuation.
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RESEARCH OBJECTIVE: Novel antipsychotic medica-
tions have several advantages over traditional agents in
the treatment of schizophrenia. Little is known about fac-
tors that affect prescribing of novel agents. This study ex-
amines variation in novel antipsychotic prescribing at 13
VA Medical Centers from six Veterans Integrated Service
Networks (VISNs). STUDY DESIGN: Using automated
data from 13 VA Medical Centers at six VISNs, we iden-
tified 740 patients with an outpatient prescription for an-
tipsychotic medication following their last discharge with
a diagnosis of schizophrenia in 1997. Most patients
(711) were male. Approximately 46% were African
American, 46% were white, and 7% were Hispanic.
Mean age was 48.5 (range 22–89). POPULATION
STUDIED: Schizophrenic patients. PRINCIPAL FIND-
INGS: Novel antipsychotic medications were prescribed
for 46.2% of the subjects, with significant variation
among the facilities (2  24.9, df  12, P  0.015,
range 26.8–58.9%) and less significant variation among
the VISNs (2  9.85, df  5, P  0.08, range 39.5–
54.4%). About 6% of the patients (46) were given depot
antipsychotic medications. Only 1 person received both
depot and novel antipsychotic medications. Although the
study population consisted of approximately equal num-
bers of white and African American subjects, 72% (33)
of the subjects prescribed depot antipsychotics were Afri-
can Americans. White patients were more likely than
non-whites to receive novel antipsychotic medications
(OR  1.836, P  0.0002) controlling for marital status,
gender, age, and facility. CONCLUSIONS: Less than
half of patients with schizophrenia are receiving novel
antipsychotic medications in this sample. In addition,
there is significant variation among facilities as well as by
ethnicity. IMPLICATIONS FOR DELIVERY AND
PRACTICE: The variation among facilities as well as by
ethnicity suggests that prescribing practices for these
agents could be improved. Further research is needed to
determine the factors that influence these practices.
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Treatment guidelines for bipolar disorder recommend
constant drug therapy with a mood stabilizing medica-
tion and prompt drug treatment for manic and depressive
episodes. The use patterns and duration of mood stabiliz-
ing therapy in real world practice are unclear. OBJEC-
TIVES: This study documents the use patterns and dura-
tion of therapy for mood stabilizing medications used to
treat bipolar disorder patients and explores the factors
that affect compliance with drug therapy. METHODS:
Medi-Cal data covering 1993–99 were used to identify
4,813 adult bipolar patients with at least one prescrip-
tion for a mood stabilizer filled during the first 12
months of their treatment episode. Compliance was de-
fined as a medication possession ratio for mood stabiliz-
ers in excess of 0.9 during the first 12 months after the
initiation of drug therapy. Logistic regression analysis
was conducted using SAS. RESULTS: 1,765 patients
(36.7%) initiated therapy on a mood stabilizer; 612
(12.7%) and 965 (20%) used an antidepressants or an-
tipsychotic as initial therapy, respectively; 1,471 (30.6%)
used multiple medications as initial therapy. The compli-
ance rate was 12.4%. A diagnosis of bipolar-manic disor-
der significantly increased the likelihood of compliance
(odds ratio  1.74), as did a diagnosis of schizophrenia
(1.33), and initiation of therapy on an atypical antipsy-
chotic (1.47). Delays in the initiation of mood stabilizer
therapy and the selection of valproic acid as the initial
mood stabilizer significantly reduced the likelihood of
compliance (odds ratio  0.642, P  0.002 for valporic
acid). CONCLUSIONS: Current drug treatment patterns
for bipolar disorder are far from ideal. Delays in mood
stabilizer use and drug selection are important determi-
nants of mood stabilizer use patterns that are consistent
with treatment guidelines.
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Scarce data exists to characterize the nature of recent sed-
ative/hypnotic use in ambulatory patients. Clinical litera-
ture suggests that use of these agents has adverse conse-
quences related to physical and mental functioning that
may be of particular concern to older individuals. Ad-
